Influence of p53 on anti-tumor immunity (Review)

International Journal of Oncology

Volumn 28, Issue 2, 2006, Pages 519-525

  Bueter, Marco ^a   Gasser, Martin ^a   Lebedeva, Tatiana ^b   Benichou, Gilles ^c   Waaga Gasser, Ana Maria ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b AMERICAN RED CROSS   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cryptic self determinants; p53; Target immunotherapy; Type 1 and 2 T cell responses

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; PROTEIN P53; TUMOR ANTIGEN;

ANIMAL; BLOOD; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MUTATION; NEOPLASM; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNE TOLERANCE; MUTATION; NEOPLASMS; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845528456     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.2.519     Document Type: Review

References (55)

1. Cho KR and Vogelstein B: Genetic alterations in the adenoma - carcinoma sequence. Cancer 70: 1727-1731, 1992.
2. Ambinder RF, Robertson KD, Moore SM and Yang J: Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol 7: 217-226, 1996.
3. Fuchs EJ, Bedi A, Jones RJ and Hess AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 55: 463-466, 1995.
4. Kawakami Y, Robbins PF, Wang RF and Rosenberg SA: Identification of tumor-regression antigens in melanoma. Important Adv Oncol 3-21, 1996.
5. Peace DJ, Chen W, Nelson H and Cheever MA: T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 146: 2059-2065, 1991.
6. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
7. Voss RH, Lotz C, Cellary A and Theobald M: Targeting p53, hdm2, and CD19: vaccination and immunologic strategies. Bone Marrow Transplant 25 (Suppl 2): S43-S45, 2000.
8. Wu TC: Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 6: 746-754, 1994.
9. Burnet FM: Immunological surveillance in neoplasia. Transplant Rev 7: 3-25, 1971.
10. Germain RN: Immunology. The ins and outs of antigen processing and presentation. Nature 322: 687-689, 1986.
11. Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J and van Waes C: Carcino-embryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 62: 5049-5057, 2002.
12. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
13. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.
14. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y and Ben-Ze'Ev A: Regulation of p53: intricate loops and delicate balances. Ann NY Acad Sci 973: 374-383, 2002.
15. Ullrich SJ, Anderson CW, Mercer WE and Appella E: The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 267: 15259-15262, 1992.
16. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
17. Coffman RL, Mocci S and O'Garra A: The stability and reversibility of Th1 and Th2 populations. Curr Top Microbiol Immunol 238: 1-12, 1999.
18. Mosmann TR and Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996.
19. Wang X and Mosmann T: In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J Exp Med 194: 1069-1080, 2001.
20. Coffman RL and Reiner SL: Instruction, selection, or tampering with the odds? Science 284: 1283-1285, 1999.
21. Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109, 2003.
22. Hernandez J, Ko A and Sherman LA: CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J Immunol 166: 3908-3914, 2001.
23. Rogel A, Popliker M, Webb CG and Oren M: p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5: 2851-2855, 1985.
24. Bargonetti J and Manfredi JJ: Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86-91, 2002.
25. Haupt Y, Robles AI, Prives C and Rotter V: Deconstruction of p53 functions and regulation. Oncogene 21: 8223-8231, 2002.
26. + T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol 164: 5641-5651, 2000.
27. Chen HL and Carbone DP: p53 as a target for anti-cancer immunotherapy. Mol Med Today 3: 160-167, 1997.
28. + T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 28: 305-316, 1998.
29. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F and Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384, 1992.
30. Rahko E, Blanco G, Soini Y, Bloigu R and Jukkola A: A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 39: 447-453, 2002.
31. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, van der Burg SH, Offringa R and Melief CJ: Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62: 6187-6193, 2002.
32. Melief CJ, van der Burg SH, Toes RE, Ossendorp F and Offringa R: Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188: 177-182, 2002.
33. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA and Claesson MH: Identification and design of p53-derived HLAA2-binding peptides with increased CTL immunogenicity. Scand J Immunol 53: 357-364, 2001.
34. Ohashi PS: Negative selection and autoimmunity. Curr Opin Immunol 15: 668-676, 2003.
35. Venanzi ES, Benoist C and Mathis D: Good riddance: thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 16: 197-202, 2004.
36. Walker LS and Abbas AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2: 11-19, 2002.
37. Ignatowicz L, Kappler J and Marrack P: The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 84: 521-529, 1996.
38. + T cells in H-2Ma0/0 mice. Immunity 7: 187-195, 1997.
39. Van Meerwijk JP, Marguerat S, Lees RK, Germain RN, Fowlkes BJ and MacDonald HR: Quantitative impact of thymic clonal deletion on the T cell repertoire. J Exp Med 185: 377-383, 1997.
40. Liblau R, Tournier-Lasserve E, Maciazek J, Dumas G, Siffert O, Hashim G and Bach MA: T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects. Eur J Immunol 21: 1391-1395, 1991.
41. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP and Link H: Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 21: 1461-1468, 1991.
42. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562, 2004.
43. Kappler JW, Staerz U, White J and Marrack PC: Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature 332: 35-40, 1988.
44. + thymocytes. Nature 333: 742-746, 1988.
45. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A and Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11: 729-766, 1993.
46. Moudgil KD and Sercarz EE: The self-directed T cell repertoire: its creation and activation. Rev Immunogenet 2: 26-37, 2000.
47. + T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus. J Exp Med 182: 1481-1491, 1995.
48. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
49. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
50. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA and Marincola FM: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163: 6292-6300, 1999.
51. Timmerman JM and Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50: 507-529, 1999.
52. Algarra I, Collado A and Garrido F: Altered MHC class I antigens in tumors. Int J Clin Lab Res 27: 95-102, 1997.
53. Chouaib S: The immunotherapy of cancer and tumor escape from immune surveillance. Funct Neurol 16: 279-283, 2001.
54. Restifo NP: Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6: 493-495, 2000.
55. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411: 380-384, 2001.